Biogen | BIIB - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.67B 140M 2026-06
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
ALKERMES USD 1.52B 164.26M 2026-06
Amgen USD 31.48B 2.42B 2026-03
Bayer EUR 35.3B 2.39B 2026-03
Biogen USD 7.31B 1.88B 2026-06
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Eli Lilly USD 54.84B 794M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Incyte USD 6.03B 542.31M 2026-06
Merck USD 35.02B 8.5B 2026-03
Moderna USD 5.82B 45M 2026-06
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Novartis USD 27.35B 744M 2026-06
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.62B 363.36M 2026-06
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 31.52B 1.36B 2026-06
Sanofi EUR 30.16B 789M 2026-03
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Teva Pharmaceutical Industries USD 13.76B 50M 2026-06
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
United Therapeutics USD 2.87B 830.5M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03